The investment will empower RDHL to develop a virtual diagnostic and care platform, expanding access to healthcare for underserved communities
Harnessing advanced data analysis for early detection, prevention and better outcomes
The CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
Partnership to supercharge LVMH Recherche with Integrated Biosciences’ innovative AI and synthetic biology platform for targeting skin aging
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
Aims to become India’s leading cancer testing company
GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
